Skip to main content
Premium Trial:

Request an Annual Quote

DeCode Slashes Loss, Sees Slight Gain in Revenues

NEW YORK, Aug. 13 (GenomeWeb News) - DeCode Genetics slashed its net loss nearly by half for the second quarter and reported narrow revenue growth today.


The company had revenue of $10.5 million for the second quarter, ending June 30, compared to $9.4 million for the year-ago quarter. Net loss was $10.2 milllion, compared to $19.7 million for the same period in 2002.


The firm cut its research and development expenditures to $16.7 million for the quarter, compared to $24 million for the second quarter, 2002.


The Iceland-based firm said it has $77 million in cash and cash equivalents at the close of the quarter on June 30.


The company said it had $12.7 million in deferred revenue, which will be recognized in future reporting periods.


The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.